أعرض في EDS

Molecular characterization of clinical responses to PD‐1/PD‐L1 inhibitors in non‐small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD‐1 inhibitors in Chinese patients

التفاصيل البيبلوغرافية
العنوان:	Molecular characterization of clinical responses to PD‐1/PD‐L1 inhibitors in non‐small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD‐1 inhibitors in Chinese patients
المؤلفون:	Kai Wang, Xiangdong Zhou, Qi Wang, Xiaoxia Cui, Xiaoyu Zhang, Chunxue Bai, Li Zhang, Jian Zhang, Jianping Zhao, Peng Song, Xiaoju Zhang, Faguang Jin, Yao Yu, Li Bai, Xiaoli Zhu, Yanbin Zhou, Chengzhi Zhou
المصدر:	Thoracic Cancer
بيانات النشر:	Wiley, 2019.
سنة النشر:	2019
مصطلحات موضوعية:	Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Adolescent, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Pembrolizumab, NSCLC, Multi‐omics, B7-H1 Antigen, Young Adult, Study Protocol, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, PD‐1/PD‐L1 inhibitor, Carcinoma, Non-Small-Cell Lung, PD-L1, Internal medicine, Biomarkers, Tumor, medicine, Humans, Molecular Targeted Therapy, predictive biomarker, Lung cancer, Aged, Response rate (survey), biology, business.industry, General Medicine, Immunotherapy, Middle Aged, medicine.disease, Clinical trial, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, biology.protein, Immunohistochemistry, Female, Nivolumab, business
الوصف:	According to multiple studies, the objective response rate of PD‐1/PD‐L1 inhibitors in the second‐line treatment of unscreened non‐small cell lung cancer (NSCLC) is only approximately 20%. Predictive biomarkers of treatment efficacies are still under investigation. In selected NSCLC patients with PD‐L1 expression ≥ 50%, the response rate of pembrolizumab in first‐line treatment can reach 44.8%. Moreover, patients with a higher tumor mutation burden (TMB) tend to achieve a better response with nivolumab. Besides PD‐L1 expression and TMB, taking all these indicators into consideration would hypothetically maximize the clinical response in a specific subgroup of patients. Our study aims to accumulate large and complete samples and clinical data to verify the biomarkers and their cutoff values related to the efficacy of PD‐1/PD‐L1 inhibitors in Chinese NSCLC patients, and to construct a comprehensive predictive model by combining multi‐omics data with contemporary machine learning techniques. NSCLC patients administered treatment of anti‐PD‐1/PD‐L1 antibodies or a combination with other drugs have been enrolled. The estimated enrollment is 250 participants. A sophisticated predictive model of immunotherapy response in the Chinese population has not yet been developed. It is clinically and practically imperative to comprehensively evaluate the possible indicators of Chinese NSCLC patients through multiple test platforms, such as next generation sequencing, PCR, or immunohistochemistry. This study is registered in the Chinese Clinical Trial Registry (ChiCTR1900021395).
تدمد:	1759-7714 1759-7706
الوصول الحر:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb9f8018da18f4739ee639337e1c7efTest https://doi.org/10.1111/1759-7714.13078Test
حقوق:	OPEN
رقم الانضمام:	edsair.doi.dedup.....adb9f8018da18f4739ee639337e1c7ef
قاعدة البيانات:	OpenAIRE

ResultId	1
Header	edsair OpenAIRE edsair.doi.dedup.....adb9f8018da18f4739ee639337e1c7ef 856 3 unknown 855.730712890625
PLink	https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....adb9f8018da18f4739ee639337e1c7ef&custid=s6537998&authtype=sso
FullText	Array ( [Availability] => 0 )
Items	Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Molecular characterization of clinical responses to PD‐1/PD‐L1 inhibitors in non‐small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD‐1 inhibitors in Chinese patients ) Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Kai+Wang%22">Kai Wang</searchLink><br /><searchLink fieldCode="AR" term="%22Xiangdong+Zhou%22">Xiangdong Zhou</searchLink><br /><searchLink fieldCode="AR" term="%22Qi+Wang%22">Qi Wang</searchLink><br /><searchLink fieldCode="AR" term="%22Xiaoxia+Cui%22">Xiaoxia Cui</searchLink><br /><searchLink fieldCode="AR" term="%22Xiaoyu+Zhang%22">Xiaoyu Zhang</searchLink><br /><searchLink fieldCode="AR" term="%22Chunxue+Bai%22">Chunxue Bai</searchLink><br /><searchLink fieldCode="AR" term="%22Li+Zhang%22">Li Zhang</searchLink><br /><searchLink fieldCode="AR" term="%22Jian+Zhang%22">Jian Zhang</searchLink><br /><searchLink fieldCode="AR" term="%22Jianping+Zhao%22">Jianping Zhao</searchLink><br /><searchLink fieldCode="AR" term="%22Peng+Song%22">Peng Song</searchLink><br /><searchLink fieldCode="AR" term="%22Xiaoju+Zhang%22">Xiaoju Zhang</searchLink><br /><searchLink fieldCode="AR" term="%22Faguang+Jin%22">Faguang Jin</searchLink><br /><searchLink fieldCode="AR" term="%22Yao+Yu%22">Yao Yu</searchLink><br /><searchLink fieldCode="AR" term="%22Li+Bai%22">Li Bai</searchLink><br /><searchLink fieldCode="AR" term="%22Xiaoli+Zhu%22">Xiaoli Zhu</searchLink><br /><searchLink fieldCode="AR" term="%22Yanbin+Zhou%22">Yanbin Zhou</searchLink><br /><searchLink fieldCode="AR" term="%22Chengzhi+Zhou%22">Chengzhi Zhou</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Thoracic Cancer ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Wiley, 2019. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2019 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%220301+basic+medicine%22">0301 basic medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Pulmonary+and+Respiratory+Medicine%22">Pulmonary and Respiratory Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Oncology%22">Oncology</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22Lung+Neoplasms%22">Lung Neoplasms</searchLink><br /><searchLink fieldCode="DE" term="%22Adolescent%22">Adolescent</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Ftreatment%22">medicine.medical_treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Programmed+Cell+Death+1+Receptor%22">Programmed Cell Death 1 Receptor</searchLink><br /><searchLink fieldCode="DE" term="%22Pembrolizumab%22">Pembrolizumab</searchLink><br /><searchLink fieldCode="DE" term="%22NSCLC%22">NSCLC</searchLink><br /><searchLink fieldCode="DE" term="%22Multi‐omics%22">Multi‐omics</searchLink><br /><searchLink fieldCode="DE" term="%22B7-H1+Antigen%22">B7-H1 Antigen</searchLink><br /><searchLink fieldCode="DE" term="%22Young+Adult%22">Young Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Study+Protocol%22">Study Protocol</searchLink><br /><searchLink fieldCode="DE" term="%2203+medical+and+health+sciences%22">03 medical and health sciences</searchLink><br /><searchLink fieldCode="DE" term="%22Antineoplastic+Agents%2C+Immunological%22">Antineoplastic Agents, Immunological</searchLink><br /><searchLink fieldCode="DE" term="%220302+clinical+medicine%22">0302 clinical medicine</searchLink><br /><searchLink fieldCode="DE" term="%22PD‐1%2FPD‐L1+inhibitor%22">PD‐1/PD‐L1 inhibitor</searchLink><br /><searchLink fieldCode="DE" term="%22Carcinoma%2C+Non-Small-Cell+Lung%22">Carcinoma, Non-Small-Cell Lung</searchLink><br /><searchLink fieldCode="DE" term="%22PD-L1%22">PD-L1</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Biomarkers%2C+Tumor%22">Biomarkers, Tumor</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Molecular+Targeted+Therapy%22">Molecular Targeted Therapy</searchLink><br /><searchLink fieldCode="DE" term="%22predictive+biomarker%22">predictive biomarker</searchLink><br /><searchLink fieldCode="DE" term="%22Lung+cancer%22">Lung cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Aged%22">Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Response+rate+%28survey%29%22">Response rate (survey)</searchLink><br /><searchLink fieldCode="DE" term="%22biology%22">biology</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22General+Medicine%22">General Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Immunotherapy%22">Immunotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trial%22">Clinical trial</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+Outcome%22">Treatment Outcome</searchLink><br /><searchLink fieldCode="DE" term="%22030104+developmental+biology%22">030104 developmental biology</searchLink><br /><searchLink fieldCode="DE" term="%22030220+oncology+%26+carcinogenesis%22">030220 oncology & carcinogenesis</searchLink><br /><searchLink fieldCode="DE" term="%22biology%2Eprotein%22">biology.protein</searchLink><br /><searchLink fieldCode="DE" term="%22Immunohistochemistry%22">Immunohistochemistry</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Nivolumab%22">Nivolumab</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => According to multiple studies, the objective response rate of PD‐1/PD‐L1 inhibitors in the second‐line treatment of unscreened non‐small cell lung cancer (NSCLC) is only approximately 20%. Predictive biomarkers of treatment efficacies are still under investigation. In selected NSCLC patients with PD‐L1 expression ≥ 50%, the response rate of pembrolizumab in first‐line treatment can reach 44.8%. Moreover, patients with a higher tumor mutation burden (TMB) tend to achieve a better response with nivolumab. Besides PD‐L1 expression and TMB, taking all these indicators into consideration would hypothetically maximize the clinical response in a specific subgroup of patients. Our study aims to accumulate large and complete samples and clinical data to verify the biomarkers and their cutoff values related to the efficacy of PD‐1/PD‐L1 inhibitors in Chinese NSCLC patients, and to construct a comprehensive predictive model by combining multi‐omics data with contemporary machine learning techniques. NSCLC patients administered treatment of anti‐PD‐1/PD‐L1 antibodies or a combination with other drugs have been enrolled. The estimated enrollment is 250 participants. A sophisticated predictive model of immunotherapy response in the Chinese population has not yet been developed. It is clinically and practically imperative to comprehensively evaluate the possible indicators of Chinese NSCLC patients through multiple test platforms, such as next generation sequencing, PCR, or immunohistochemistry. This study is registered in the Chinese Clinical Trial Registry (ChiCTR1900021395). ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1759-7714<br />1759-7706 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb9f8018da18f4739ee639337e1c7ef" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb9f8018da18f4739ee639337e1c7ef</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1111/1759-7714.13078" linkWindow="_blank">https://doi.org/10.1111/1759-7714.13078</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....adb9f8018da18f4739ee639337e1c7ef )
RecordInfo	Array ( [BibEntity] => Array ( [Languages] => Array ( [0] => Array ( [Text] => Undetermined ) ) [PhysicalDescription] => Array ( [Pagination] => Array ( [PageCount] => 7 [StartPage] => 1303 ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => Adult [Type] => general ) [1] => Array ( [SubjectFull] => Male [Type] => general ) [2] => Array ( [SubjectFull] => 0301 basic medicine [Type] => general ) [3] => Array ( [SubjectFull] => Pulmonary and Respiratory Medicine [Type] => general ) [4] => Array ( [SubjectFull] => Oncology [Type] => general ) [5] => Array ( [SubjectFull] => medicine.medical_specialty [Type] => general ) [6] => Array ( [SubjectFull] => Lung Neoplasms [Type] => general ) [7] => Array ( [SubjectFull] => Adolescent [Type] => general ) [8] => Array ( [SubjectFull] => medicine.medical_treatment [Type] => general ) [9] => Array ( [SubjectFull] => Programmed Cell Death 1 Receptor [Type] => general ) [10] => Array ( [SubjectFull] => Pembrolizumab [Type] => general ) [11] => Array ( [SubjectFull] => NSCLC [Type] => general ) [12] => Array ( [SubjectFull] => Multi‐omics [Type] => general ) [13] => Array ( [SubjectFull] => B7-H1 Antigen [Type] => general ) [14] => Array ( [SubjectFull] => Young Adult [Type] => general ) [15] => Array ( [SubjectFull] => Study Protocol [Type] => general ) [16] => Array ( [SubjectFull] => 03 medical and health sciences [Type] => general ) [17] => Array ( [SubjectFull] => Antineoplastic Agents, Immunological [Type] => general ) [18] => Array ( [SubjectFull] => 0302 clinical medicine [Type] => general ) [19] => Array ( [SubjectFull] => PD‐1/PD‐L1 inhibitor [Type] => general ) [20] => Array ( [SubjectFull] => Carcinoma, Non-Small-Cell Lung [Type] => general ) [21] => Array ( [SubjectFull] => PD-L1 [Type] => general ) [22] => Array ( [SubjectFull] => Internal medicine [Type] => general ) [23] => Array ( [SubjectFull] => Biomarkers, Tumor [Type] => general ) [24] => Array ( [SubjectFull] => medicine [Type] => general ) [25] => Array ( [SubjectFull] => Humans [Type] => general ) [26] => Array ( [SubjectFull] => Molecular Targeted Therapy [Type] => general ) [27] => Array ( [SubjectFull] => predictive biomarker [Type] => general ) [28] => Array ( [SubjectFull] => Lung cancer [Type] => general ) [29] => Array ( [SubjectFull] => Aged [Type] => general ) [30] => Array ( [SubjectFull] => Response rate (survey) [Type] => general ) [31] => Array ( [SubjectFull] => biology [Type] => general ) [32] => Array ( [SubjectFull] => business.industry [Type] => general ) [33] => Array ( [SubjectFull] => General Medicine [Type] => general ) [34] => Array ( [SubjectFull] => Immunotherapy [Type] => general ) [35] => Array ( [SubjectFull] => Middle Aged [Type] => general ) [36] => Array ( [SubjectFull] => medicine.disease [Type] => general ) [37] => Array ( [SubjectFull] => Clinical trial [Type] => general ) [38] => Array ( [SubjectFull] => Treatment Outcome [Type] => general ) [39] => Array ( [SubjectFull] => 030104 developmental biology [Type] => general ) [40] => Array ( [SubjectFull] => 030220 oncology & carcinogenesis [Type] => general ) [41] => Array ( [SubjectFull] => biology.protein [Type] => general ) [42] => Array ( [SubjectFull] => Immunohistochemistry [Type] => general ) [43] => Array ( [SubjectFull] => Female [Type] => general ) [44] => Array ( [SubjectFull] => Nivolumab [Type] => general ) [45] => Array ( [SubjectFull] => business [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Molecular characterization of clinical responses to PD‐1/PD‐L1 inhibitors in non‐small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD‐1 inhibitors in Chinese patients [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kai Wang ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Xiangdong Zhou ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Qi Wang ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Xiaoxia Cui ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Xiaoyu Zhang ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Chunxue Bai ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Li Zhang ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jian Zhang ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jianping Zhao ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Peng Song ) ) ) [10] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Xiaoju Zhang ) ) ) [11] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Faguang Jin ) ) ) [12] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Yao Yu ) ) ) [13] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Li Bai ) ) ) [14] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Xiaoli Zhu ) ) ) [15] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Yanbin Zhou ) ) ) [16] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Chengzhi Zhou ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 23 [M] => 04 [Type] => published [Y] => 2019 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 17597714 ) [1] => Array ( [Type] => issn-print [Value] => 17597706 ) [2] => Array ( [Type] => issn-locals [Value] => edsair ) [3] => Array ( [Type] => issn-locals [Value] => edsairFT ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 10 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Thoracic Cancer [Type] => main ) ) ) ) ) ) )
IllustrationInfo